United States
Yeshiva University - Division of Infectious Disease
convalescent plasma, COVID-19, passive-antibody therapy, SARS-CoV-2
COVID-19, SARS-CoV-2, Convalescent plasma, Functional antibodies, Fc modification, antibody glycosylation, antibody therapeutics, nucleocapsid, shifts in immunodominance, immunomodulation, COVID therapeutics